Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.88
+2.3%
$13.44
$6.69
$16.73
$782.24M1.9965,664 shs736,306 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$49.12
+2.8%
$42.05
$14.78
$50.56
$2.91B0.291.97 million shs2.77 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$64.34
-4.1%
$62.57
$38.51
$85.25
$2.89B0.49622,808 shs510,853 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
+2.32%+5.80%+13.75%+103.07%+122.41%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+2.83%+8.91%+15.49%+26.50%+128.47%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-4.13%+1.87%+5.20%-2.88%+60.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.88
+2.3%
$13.44
$6.69
$16.73
$782.24M1.9965,664 shs736,306 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$49.12
+2.8%
$42.05
$14.78
$50.56
$2.91B0.291.97 million shs2.77 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$64.34
-4.1%
$62.57
$38.51
$85.25
$2.89B0.49622,808 shs510,853 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
+2.32%+5.80%+13.75%+103.07%+122.41%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+2.83%+8.91%+15.49%+26.50%+128.47%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-4.13%+1.87%+5.20%-2.88%+60.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$15.11-4.84% Downside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.83
Moderate Buy$63.4029.07% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.78
Moderate Buy$90.6740.92% Upside

Current Analyst Ratings Breakdown

Latest CYRX, ELVN, MOR, and TARS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Initiated CoverageBuy$60.00
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$13.50
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingHold$13.00
6/3/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $20.00
6/2/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Boost Price TargetOutperform$45.00 ➝ $62.00
5/20/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetOverweight$15.00 ➝ $17.00
5/12/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Initiated CoverageBuy$80.00
5/11/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
UpgradeStrong-Buy
5/8/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Boost Price TargetBuy$41.00 ➝ $59.00
5/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
UpgradeSell (D+)Hold (C-)
5/5/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$11.00 ➝ $12.00
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.54N/AN/A$9.19 per share1.73
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$7.74 per shareN/A
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$451.36M6.13N/AN/A$8.09 per share7.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3511.76N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$66.42M-$1.14N/A22.03N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)

Latest CYRX, ELVN, MOR, and TARS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.44-$0.38+$0.06-$0.38N/AN/A
5/6/2026Q1 2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
40.32
40.32
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
3.74
3.71

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
9.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5060.90 million59.08 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5043.02 million38.88 millionOptionable

Recent News About These Companies

Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work
Tarsus Pharmaceuticals Inc.
Tarsus to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CryoPort stock logo

CryoPort NASDAQ:CYRX

$15.88 +0.36 (+2.32%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$15.86 -0.02 (-0.13%)
As of 06/25/2026 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$49.12 +1.35 (+2.83%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$49.11 -0.01 (-0.02%)
As of 06/25/2026 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 06/24/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$64.34 -2.77 (-4.13%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$64.35 +0.01 (+0.02%)
As of 06/25/2026 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.